Stylage Bi-Soft M™
Hyaluronic Acid Dermal Filler
Stylage Bi-Soft M™ is a cross-linked hyaluronic acid filler containing 20mg/g concentration, specifically formulated for superficial line correction. Clinical studies show 89% patient satisfaction rate with immediate visible results. The innovative MANNITOL™ technology provides antioxidant protection while maintaining natural facial expressions. Recommended for patients aged 25-65 with mild to moderate skin laxity.
- Precision Correction: Ideal for superficial wrinkles (0.5-2mm depth) with 27G needle compatibility
- Multi-Zone Application: Suitable for facial contours, nasal reshaping, and hand rejuvenation
- Longevity: Up to 12-month duration with optimal tissue integration
- Natural Results: Maintains facial expressiveness while correcting lines
Cross-linked Hyaluronic Acid
MANNITOL™ antioxidant protection
Pre-filled syringes with compatible needles
Controlled room temperature; protect from light
Standard unopened shelf life
Contraindications: Active skin infections, bleeding disorders, or hypersensitivity to gram-positive bacterial proteins
Adverse Effects: Temporary swelling, redness, or bruising may occur
Professional Note: Individual results may vary based on injection technique and tissue quality
• Stylage Bi-Soft M™ requires prescription and professional administration
• Must be administered by licensed practitioners only
• Always follow aseptic techniques during administration
• Monitor for vascular complications during injection
• Manufacturer not liable for complications arising from off-label use
We are an authorized wholesale distributor of medical aesthetic products. This product information is provided for professional healthcare providers only. We do not sell directly to end-users. All products must be prescribed and administered by qualified medical professionals in accordance with local regulations. For actual product specifications, please contact our sales team as packaging may vary. Product images are for reference only.
Reviews
There are no reviews yet.